{{Rsnum
|rsid=903361
|Chromosome=1
|position=203122146
|Orientation=minus
|GMAF=0.3471
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 6.2 | 52.3 | 41.5
| HCB | 22.2 | 53.3 | 24.4
| JPT | 15.9 | 40.9 | 43.2
| YRI | 14.3 | 38.1 | 47.6
| ASW | 0.0 | 0.0 | 0.0
| CHB | 22.2 | 53.3 | 24.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs903361
|Name_s=
|Gene_s=ADORA1
|Feature=
|Evidence=PubMed ID:18996102
|Annotation=In a study conducted in 87 outpatients with type 2 diabetes receiving thiazolidinedione therapy this SNP located in intron 2 of the ADORA1 gene (rs903361C/T, p<0.0003) was significantly associated with the risk of high Body mass index.
|Drugs=
|Drug Classes=THIAZOLIDINEDIONES
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA165107438
}}

{{PMID Auto
|PMID=20609566
|Title=Adenosine A1 receptor gene variants associated with post-traumatic seizures after severe TBI.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs903361
|overall_frequency_n=92
|overall_frequency_d=128
|overall_frequency=0.71875
|n_genomes=53
|n_genomes_annotated=0
|n_haplomes=80
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}